BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Hank readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Hank\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07125872-2204@assetmemo.bio
DTSTAMP:20261121T004024Z
DTSTART;VALUE=DATE:20270525
DTEND;VALUE=DATE:20270526
SUMMARY:Hank: Phase 2 readout est. (NCT07125872)
DESCRIPTION:Hank\, phase 2.\nStudy: Study of Relapsed/ Refractory B-cell No
 n- Hodgkin Lymphoma\nEstimated primary completion: 25 May 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/hank#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07125872
URL:https://assetmemo.bio/drug/hank#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02727803-2204@assetmemo.bio
DTSTAMP:20261121T004024Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Hank: Phase 2 readout est. (NCT02727803)
DESCRIPTION:Hank\, phase 2.\nStudy: Personalized NK Cell Therapy in CBT\nEs
 timated primary completion: 31 May 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/hank#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT02727803
URL:https://assetmemo.bio/drug/hank#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06334991-2204@assetmemo.bio
DTSTAMP:20261121T004024Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Hank: Phase 1 readout est. (NCT06334991)
DESCRIPTION:Hank\, phase 1.\nStudy: Study for Participants With Relapsed/Re
 fractory Non-Hodgkin Lymphoma\nEstimated primary completion: October 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/hank#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06334991
URL:https://assetmemo.bio/drug/hank#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07477366-2204@assetmemo.bio
DTSTAMP:20261121T004024Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Hank: Phase 2 readout est. (NCT07477366)
DESCRIPTION:Hank\, phase 2.\nStudy: Study of CD19 t-haNK and NAI With Ritux
 imab in Participants With Indolent Non-Hodgkin Lymphoma\nEstimated primary
  completion: December 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/hank#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07477366
URL:https://assetmemo.bio/drug/hank#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06061809-2204@assetmemo.bio
DTSTAMP:20261121T004024Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Hank: Phase 2 readout est. (NCT06061809)
DESCRIPTION:Hank\, phase 2.\nStudy: N-803 and PD-L1 t-haNK Combined With Be
 vacizumab for Recurrent or Progressive Glioblastoma\nEstimated primary com
 pletion: 31 December 2029. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/hank#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06061809
URL:https://assetmemo.bio/drug/hank#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
